TearLab Corporation develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, Calif., TearLab Corporation's common shares trade on the NASDAQ.
Partial Data by Infogroup (c) 2024. All rights reserved.
Partial Data by Foursquare.